Pediatrix Medical Group, Inc.

NYSE:MD Stock Report

Market Cap: US$1.2b

Pediatrix Medical Group Valuation

Is MD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MD ($14.61) is trading below our estimate of fair value ($39.32)

Significantly Below Fair Value: MD is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MD?

Key metric: As MD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MD. This is calculated by dividing MD's market cap by their current revenue.
What is MD's PS Ratio?
PS Ratio0.6x
SalesUS$2.01b
Market CapUS$1.22b

Price to Sales Ratio vs Peers

How does MD's PS Ratio compare to its peers?

The above table shows the PS ratio for MD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.7x
AVAH Aveanna Healthcare Holdings
0.6x4.8%US$1.1b
AGTI Agiliti
1.2x5.9%US$1.4b
PNTG Pennant Group
1.7x13.3%US$1.1b
WGS GeneDx Holdings
7.3x17.1%US$2.0b
MD Pediatrix Medical Group
0.6x-0.2%US$1.2b

Price-To-Sales vs Peers: MD is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (2.7x).

Price to Sales Ratio vs Industry

How does MD's PS Ratio compare vs other companies in the US Healthcare Industry?

32 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$78.14b
CVS CVS Health
0.2x4.7%US$70.53b
COR Cencora
0.2x6.4%US$47.60b
CNC Centene
0.2x5.6%US$29.70b
MD 0.6xIndustry Avg. 1.0xNo. of Companies32PS012345+
32 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MD is good value based on its Price-To-Sales Ratio (0.6x) compared to the US Healthcare industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is MD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio0.5x

Price-To-Sales vs Fair Ratio: MD is expensive based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$14.61
US$15.92
+8.9%
6.9%US$18.00US$15.00n/a6
Nov ’25US$15.21
US$11.58
-23.8%
15.8%US$14.00US$9.00n/a6
Oct ’25US$12.00
US$10.58
-11.8%
15.0%US$14.00US$9.00n/a6
Sep ’25US$10.86
US$9.58
-11.8%
8.7%US$10.50US$8.00n/a6
Aug ’25US$8.25
US$8.21
-0.4%
6.4%US$9.00US$7.50n/a7
Jul ’25US$7.11
US$8.50
+19.5%
9.4%US$10.00US$7.50n/a7
Jun ’25US$7.31
US$9.00
+23.1%
5.9%US$10.00US$8.00n/a7
May ’25US$9.01
US$9.07
+0.7%
6.2%US$10.00US$8.00n/a7
Apr ’25US$9.74
US$9.07
-6.9%
6.2%US$10.00US$8.00n/a7
Mar ’25US$8.77
US$9.36
+6.7%
9.3%US$11.00US$8.00n/a7
Feb ’25US$9.60
US$9.86
+2.7%
7.0%US$11.00US$9.00n/a7
Jan ’25US$9.30
US$10.07
+8.3%
10.1%US$12.00US$9.00n/a7
Dec ’24US$8.77
US$10.64
+21.4%
10.3%US$12.00US$9.00n/a7
Nov ’24US$11.21
US$14.50
+29.3%
3.4%US$15.00US$14.00US$15.216
Oct ’24US$12.71
US$15.00
+18.0%
5.4%US$16.00US$14.00US$12.006
Sep ’24US$13.97
US$16.14
+15.6%
18.0%US$23.00US$14.00US$10.867
Aug ’24US$13.66
US$16.00
+17.1%
18.3%US$23.00US$14.00US$8.257
Jul ’24US$14.21
US$16.00
+12.6%
18.3%US$23.00US$14.00US$7.117
Jun ’24US$13.56
US$16.00
+18.0%
18.3%US$23.00US$14.00US$7.317
May ’24US$14.33
US$17.07
+19.1%
16.0%US$23.00US$14.00US$9.017
Apr ’24US$14.91
US$17.69
+18.6%
13.5%US$23.00US$15.00US$9.748
Mar ’24US$15.45
US$17.69
+14.5%
13.5%US$23.00US$15.00US$8.778
Feb ’24US$15.75
US$18.00
+14.3%
20.4%US$27.00US$14.00US$9.608
Jan ’24US$14.86
US$18.13
+22.0%
20.0%US$27.00US$14.00US$9.308
Dec ’23US$16.24
US$18.25
+12.4%
21.5%US$28.00US$14.00US$8.778
Nov ’23US$19.54
US$20.88
+6.8%
15.6%US$28.00US$16.00US$11.218

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Patterson Companies

US$1.8b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$20.41

7D

-1.7%

1Y

-36.8%

Centene

US$29.7b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$57.81

7D

-1.3%

1Y

-21.6%

CVS Health

US$70.5b

Provides health solutions in the United States.

CVS

US$55.77

7D

3.2%

1Y

-18.1%